Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LT-4010
- Development stage
- Unknown
- Lead developer
- LTT Bio-Pharma
- Modality
- Small Molecules
01
Overview
LT-4010 is a small molecule drug candidate being developed by LTT Bio-Pharma (LTBIO) through a drug repositioning strategy. It is currently in Phase 1 clinical development for the treatment of pulmonary fibrosis. Drug repositioning involves identifying new therapeutic uses for existing drugs, which can potentially shorten development timelines and reduce costs. While the specific identity of the original small molecule has not been publicly disclosed in the provided pipeline summaries, it represents LTBIO's expansion into fibrotic lung disease treatments beyond their superoxide dismutase (SOD) based delivery systems.
- Other names
- Drug re-positioning (DR)
Beyond the preview
Go deeper on LT-4010.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LT-4010.